The 02-sensitive reduction of high-molecular-weight aromatic azo and nitro dyes by intestinal bacteria appears to be mediated by low-molecular-weight electron carriers with Eo' = -200 to -350 mV. This process may allow the design of polymeric azo prodrugs for specific release of certain aromatic amines in the colon.
The ability of the intestinal microflora to reduce the azo and nitro groups of various xenobiotic compounds has been known for many years (15, 19) . Whereas enzymatic reduction of azo compounds has been demonstrated with hepatic microsomes (12) and cytosol (13) , the specific components ofthe intestinal microflora participating in azo or nitro reduction and the mechanisms of these processes are poorly understood (1, 6, 14) . This study was initiated by the finding that intestinal bacteria under anaerobic conditions could reduce high-molecular-weight polymeric derivatives of certain azo dyes at rates comparable with those of the low-molecularweight parent compounds, despite large differences in the membrane permeabilities of these agents (J. P. Brown, Abstr. Annu. Meet. Am. Soc. Microbiol. 1976, I72, p. 123).
The objective of this report is to present data on the reduction of high-molecular-weight polymeric azo and nitro dyes by intestinal bacteria and their enzymic extracts and to evaluate these and other data with respect to the probable mechanism(s) affecting azo and nitro reduction of poorly permeable xenobiotic compounds in the mammalian lower bowel.
(A preliminary report of this study was presented at the XII Intemational Congress of Microbiology, Munich, Gennany).
The polymeric azo dyes used in this study are based on the food dyes sunset yellow (FD&C yellow no. 6) and tartrazine (FD&C yellow no. 5) and have been described previously (4, 9) . In addition, a similar polymeric derivative of 4-amino-5-nitrobenzene sulfonic acid sodium salt was employed ( Fig. 1 and D (3) .
The similarities demonstrated between azo reduction and nitro reduction, their hepatic and intestinal bacterial catalyses (18) and sensitivity to oxygen (11) , and the possibility of their fonning free radical internediates (11) and low-molecular-weight azo dyes (3). In our laboratory, benzyl viologen has proved to be the most effective mediator of both azo and nitro reduction by bacterial cell suspensions. The reduction of azo and nitro polymers was next investigated in cell-free preparations of rat cecal bacteria. Whereas both azo and nitro reduction could be demonstrated in crude cell-free extracts containing a reduced nicotinamide adenine dinucleotide-generating system and benzyl viologen, the azo-reducing activity was much enhanced by gel filtering these extracts to remove small molecules ( Table 3 ). The reduction of azo dyes in the presence of benzyl viologen was rapid and zero order to very low substrate dye concentrations. This process is oxygen sensitive since the reduced mediator is usually autooxidizable. In addition to this rapid carrier-mediated azo reduction, two other processes were apparent. In the absence of mediator and under aerobic conditions, a reduced nicotinamide adenine dinucleotide-dependent azo reduction proceeds at a very slow rate (-9 nmol h-' ml-' with sunset yellow). Under anaerobic conditions without mediator, both azo and nitro reduction proceed slowly. Findings similar to these have been reported for a number of low-molecularweight azo dyes with crude cell-free extracts of Streptococcus faecales (6), Fusobacterium sp. 2 (7), reduced nicotinamide adenine dinucleotide, and flavin mononucleotide (FMN).
In summary, whereas the hypothesis of extracellular reduction of azo and nitro compounds by small molecules has not been proven, most of the key findings can best be explained by such a mechanism acting in concert, perhaps with intracellular "azo and nitro reductases." These findings may be summarized as follows: (i) relatively rapid reduction of high-molecular-weight azo and nitro compounds with low permeability; (ii) relatively little structure and activity correlation with respect to the reduction of azo dyes by intestinal bacteria (10, 16, 17) ; (iii) stimula- (9) . This latter point is the basis for the design of a new class of site-specific controlled-release polymeric prodrugs for the therapy of lower bowel and possibly other diseases (T. M. Parkinson, J. P. Brown, R. E. Wingard, Jr., U.S. patent 4,190,176, 26 Feb. 1980 ).
